

Contents

Foreword	IX
1 Cardiac physiology of acute heart failure syndromes	1
1.1 Cardiac performance	2
1.2 The fundamental equation of the circulation	3
1.3 Preload	4
a) Definition	4
b) Frank–Starling mechanism	4
c) Venous return and CVP in daily practice	8
1.4 Haemodynamic monitoring	10
a) Assessment and monitoring of fluid status	10
b) Prediction of fluid responsiveness	12
i) Pressure measurements	12
ii) Volumetric measurements	12
iii) Dynamic parameters	13
iv) Fluid challenge	16
v) PiCCO-monitoring	17
vi) Echocardiography	19
c) Arterial blood pressure	20
i) BP and autoregulation	20
ii) Assessment of tissue perfusion	21
1.5 Afterload	22
a) Definition	22
b) Estimation, measurements and interpretation	22
c) Afterload in acute heart failure syndromes	25
1.6 Contractility	26
a) Definition	26
b) Measurement and quantification	26
c) Inotropic medications	29
1.7 Heart rate and contractility	30
1.8 Diastolic ventricular interaction (DVI)	31
a) Definition	31
b) Septum and trans-septal pressure	32
c) Pericardium	32
d) Pulmonary hypertension and the risk of DVI	33
e) Acutely exacerbated chronic congestive (left-sided or biventricular) HF	34
f) Conclusions	37
1.9 Ventriculo-arterial coupling	37
a) Definition	37
b) Arterial elastance	38
c) Ventricular elastance	38

	d) Ventriculo-arterial coupling	39
	e) Deranged coupling	40
1.10	Evaluation and assessment of cardiac performance	41
1.11	Summary	43
	a) Key physiology	43
	b) Afterload	44
	c) Systolic function	44
	d) Volume status	44
	e) Ventriculo-arterial coupling	45
	f) DVI	45
	g) Echocardiography	45
2	Acute heart failure syndromes	47
2.1	Definition	48
2.2	Classification of acute heart failure syndromes (AHFS)	48
2.3	Aetiology and epidemiology	49
2.4	Pathophysiology	50
	a) The fundamental pathophysiological changes in AHFS	50
	b) Pathophysiology and symptoms	51
2.5	Data on clinical presentation and diagnosis	52
	a) Presentation	52
	b) Predictors of mortality	52
	c) Clinical haemodynamic profiles	53
	d) Echocardiography, X-ray, ECG and serum markers	54
	e) The CPI–SVRI relation	56
2.6	Therapy	56
	a) Therapeutic principles and goals	56
	b) Treatment of underlying disease	59
	c) Essential measures	59
	i) Vasodilators	59
	ii) Diuretics and continuous renal replacement therapy (CRRT)	61
	iii) Inotropic drugs and vasopressor therapy	62
	iv) Arrhythmias and heart failure	66
	v) CPAP and NIPPV	66
	vi) Anticoagulation	67
2.7	Valvular heart disease presenting as heart failure	67
	a) Mitral regurgitation	67
	b) Mitral stenosis	68
	c) Aortic regurgitation	68
	d) Aortic stenosis	69
2.8	Summary	70
3	Cardiogenic shock	71
3.1	Definition	72
3.2	Epidemiology	72
3.3	Aetiology	73

3.4	Pathophysiological aspects and special features	73
	a) Classical pathophysiology and new CS paradigm	73
	b) The role and impact of hypotension in CS	76
	c) Myocardial ischaemia and LV- compliance	76
	d) Other acute causes of a substantial impairment in contractility	77
3.5	Clinical features and diagnostic remarks.	77
	a) Hypoperfusion	77
	b) Right ventricular infarction	78
	c) The LVEDP in cardiogenic shock.	79
	d) Differential diagnosis of cardiogenic shock	80
3.6	Therapy	80
	a) Main therapeutic strategies.	80
	b) Adjunctive treatment	82
	i) Re-establishing and maintaining appropriate coronary and systemic perfusion	82
	ii) Fluid administration.	82
	iii) Vasopressor administration.	82
	iv) Intra-aortic balloon counter pulsation	83
	v) Inotropic medication	83
	c) The systemic inflammatory reaction	84
	d) Renal function	84
	e) Compensation of acidosis.	85
	f) Anticoagulation therapy.	85
3.7	Summary	85
4	Acute right heart failure	89
4.1	Definition	90
4.2	Epidemiology and aetiology.	90
4.3	Physiological and pathophysiological aspects	91
	a) General physiology.	91
	b) Diastolic ventricular interactions	93
	c) The role of the pericardium in diastolic ventricular interaction.	94
	d) Auto-aggravation	94
	e) Series Effect	95
	f) Pulmonary hypertension and ischaemia	95
	g) The interventricular septum and the apex.	96
	h) The left ventricle.	96
	i) Mechanical ventilation	97
4.4	Diagnostic aspects	99
	a) Clinical features	99
	b) Serum biomarkers	99
	c) Electrocardiography	100
	d) Echocardiography.	100
4.5	Therapy	102
	a) Specific measures	102
	b) Adjunctive therapy.	103

	i) Fluid management and optimization of preload	103
	ii) Vasopressors: Treatment and avoidance of ischaemia.	104
	iii) Critical RV-afterload reduction.	105
	iv) Improvement of RV systolic Function / Contractility.	106
	v) Intra-aortic balloon pump	107
	vi) Hypercapnia and acidosis	107
	vii) Oxygen therapy	107
	viii) AV sequential stimulation.	107
	ix) Mechanical ventilation	108
	x) Diuretics	108
	xi) Anticoagulation	108
	xii) Digoxin	108
	c) Therapeutic conclusions	108
4.6	Summary	109
	a) Summary of clinical features.	109
	b) Summary of treatment	110
5	Heart failure with normal left ventricular ejection fraction (HFNEF)	113
5.1	Definition	114
5.2	Epidemiology and aetiology	114
5.3	Pathophysiology.	115
	a) Abnormal relaxation and reduced LV compliance.	115
	b) Factors/mechanisms triggering development of acute heart failure	117
	i) Ischaemia	117
	ii) Abnormalities in afterload and ventriculo-arterial (v-a) coupling	117
	c) Conclusion.	119
5.4	Clinical Features	119
	a) Clinical appearance and general remarks	119
	b) Diastolic pressure-volume relation	120
	c) LV systolic function	122
	d) Echocardiographic parameters of diastolic dysfunction.	123
	i) Difference between Ard time and Ad time	124
	ii) Tissue Doppler assessment	124
	iii) LA volume index (LAVI)	125
	iv) End diastolic LV volume (LVEDE).	125
	v) Concentric LV hypertrophy	125
	e) Biomarkers.	126
5.5	Therapeutic considerations.	126
5.6	Summary	127
	References	129
	Index	173
	Abbreviations	177